Preliminary results from SpectraCure's prostate treatments
Preliminary results have been reported from the latest patient treatments in SpectraCure's clinical trial for the treatment of patients with recurrent prostate cancer, at University College London Hospital. A very clear treatment effect is seen on MR images in the treatment area, indicating destruction of the tumour, just like previously treated patients with the high drug dose.In the patients where follow-up of PSA values has been made, very clear reduction of PSA is seen after treatment, with decreases in the range of 50-73%."It is very gratifying that we get continued good results,"